Table 2 BRB consumption decreased UBT and inflammatory markers, and oxidative indexes
Week 0 | Week 8 | Follow up | |
---|---|---|---|
UBT | |||
BRBs | 22.12 ± 4.14 | 9.36 ± 6.36a | 16.82 ± 10.46a |
Placebo | 22.98 ± 1.78 | 22.99 ± 2.065 | 22.88 ± 3.07 |
Inflammatory markers | |||
TNF-α (pg/mL) | |||
BRBs | 19.76 ± 4.65 | 6.85 ± 3.27a | 7.97 ± 2.17a |
Placebo | 19.81 ± 2.21 | 19.59 ± 2.31 | 19.41 ± 2.39 |
IL-1β (pg/mL) | |||
BRBs | 0.16 ± 0.07 | 0.12 ± 0.05a | 0.18 ± 0.05a |
Placebo | 0.19 ± 0.08 | 0.19 ± 0.05 | 0.18 ± 0.05 |
IL-8 (pg/mL) | |||
BRBs | 7.61 ± 5.10 | 4.63 ± 3.63a | 5.94 ± 3.09 |
Placebo | 7.67 ± 4.25 | 7.86 ± 4.90 | 7.79 ± 4.23 |
COX-2 (ng/mL) | |||
BRBs | 1.74 ± 0.71 | 0.87 ± 0.56a | 0.88 ± 0.50a |
Placebo | 1.68 ± 0.65 | 1.64 ± 0.72 | 1.69 ± 0.62 |
iNOS (ng/mL) | |||
BRBs | 21.15 ± 8.50 | 20.27 ± 10.28 | 22.37 ± 11.95 |
Placebo | 21.73 ± 7.44 | 22.00 ± 7.75 | 21.21 ± 7.24 |
Oxidative indexes | |||
SOD (U/mL) | |||
BRBs | 696.42 ± 35.30 | 784.86 ± 46.13a | 743.84 ± 55.59a |
Placebo | 690.72 ± 34.84 | 695.44 ± 39.65 | 691.54 ± 41.35 |
CAT (U/mL) | |||
BRBs | 346.11 ± 14.60 | 360.84 ± 8.26a | 360.21 ± 9.22a |
Placebo | 352.58 ± 14.16 | 351.95 ± 11.30 | 351.14 ± 9.03 |
TBARS (µmol/L) | |||
BRBs | 4.14 ± 1.20 | 1.20 ± 0.35a | 1.97 ± 0.62a |
Placebo | 4.20 ± 0.57 | 4.25 ± 0.74 | 4.30 ± 0.90 |
TEAC (µmol Trolox/L) | |||
BRBs | 1319.77 ± 191.90 | 1840.68 ± 188.73a | 1740.09 ± 155.99a |
Placebo | 1250.90 ± 185.14 | 1232.00 ± 199.59 | 1238.40 ± 237.70 |